HCW Biologics shares surge 14.04% after-hours on breakthrough second-generation cancer immunotherapy and multi-billion-dollar market potential.

HCW Biologics (NASDAQ:HCWB) surged 14.04% in after-hours trading, driven by multiple reports highlighting breakthroughs in its second-generation cancer immunotherapy pipeline. Key announcements included the development of a novel immune checkpoint inhibitor with potential multi-billion-dollar market implications and positive IND-enabling study results for pembrolizumab-based treatments targeting solid tumors. These advancements, showcased in late August 2025, reinforced investor optimism about the company’s oncology platform and commercial prospects. While earlier news in June 2025 about a licensing agreement with WY Biotech initially caused volatility, recent focus on clinical progress and preclinical success overshadowed prior concerns, aligning with the sharp post-market rally.